共 38 条
Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study
被引:0
|作者:
Chen, Ruo-Yang
[1
]
Li, Da -Wei
[1
]
Wang, Jie-Ying
[2
]
Zhuang, Shao-Yong
[1
]
Wu, Hao-Yu
[1
]
Wu, Jia-Jin
[1
]
Qu, Jun-Wen
[1
]
Sun, Nan
[1
]
Zhong, Chen
[1
]
Zhu, Cheng
[3
]
Zhang, Ming
[1
,5
]
Yu, Yue-Tian
[4
,5
]
Yuan, Xiao-Dong
[1
,5
]
机构:
[1] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Urol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Dept Clin Res Ctr, Sch Med, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Dis Prevent & Control, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Crit Care Med, Shanghai, Peoples R China
[5] 145 Middle Shandong Rd, Shanghai, Peoples R China
关键词:
Trimethoprim-sulfamethoxazole;
Kidney transplantation;
Pneumocystis jirovecii pneumonia;
Fungal infection;
Prophylaxis;
D O I:
暂无
中图分类号:
R51 [传染病];
学科分类号:
100401 ;
摘要:
Objectives: To evaluate the efficacy and safety of low-dose trimethoprim (TMP)-sulfamethoxazole (SMX) (TMP-SMX) as the primary prophylaxis for Pneumocystis jirovecii pneumonia (PJP) in adult recipients of kidney transplantation.Methods: Three kinds of prescriptions in kidney recipients were documented, including 20 mg TMP/100 mg SMX oral daily, 20 mg TMP/100 mg SMX oral every other day, and nonprophylaxis. The primary outcome was the incidence of PJP in the first 180 days of follow-up after kidney transplantation. The secondary outcomes were changes in renal and liver function.Results: Among the 1469 recipients, 1066 (72.56%) received 20 mg TMP/100 mg SMX daily, 127 (8.65%) received 20 mg TMP/100 mg SMX every other day, and 276 (18.79%) did not have prophylaxis prescrip-tion. The 276 recipients in the nonprophylaxis group had 124.92 person-years of follow-up, during which PJP occurred in 29 patients, for an incidence rate of 23.21 (95% confidence interval 15.76-32.72) per 100 person-years. The TMP-SMX daily group and the TMP-SMX every other day group had 524.89 and 62.07 person-years of follow-up, respectively, with no occurrence of PJP. There was no significant difference among the three groups in changes in renal and liver function ( P > 0.05, respectively). A total of 111 recipients in each group were enrolled in the propensity score matching analysis. It was revealed that the 111 nonprophylaxis recipients had 51.27 person-years of follow-up and 10 PJP cases. Prophylaxis was considered effective because there was a significant difference between the three groups ( P < 0.001).Conclusion: Low-dose TMP-SMX prophylaxis significantly reduces the incidence of PJP within 6 months after kidney transplantation and has a favorable safety profile.& COPY; 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:209 / 215
页数:7
相关论文